Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2012-11-29T18:54:35Z No. of bitstreams: 1 Helder Jacobina Santos As y-glutamil... 2005.pdf: 33243351 bytes, checksum: 707639696a2cd425ea90f9fb81248893 (MD5) / Made available in DSpace on 2012-11-29T18:54:35Z (GMT). No. of bitstreams: 1 Helder Jacobina Santos As y-glutamil... 2005.pdf: 33243351 bytes, checksum: 707639696a2cd425ea90f9fb81248893 (MD5) Previous issue date: 2005 / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil / A carbamazepina é a droga de eleição usada no tratamento de pacientes com epilepsia secundariamente generalizada. Além disso, a carbamazepina tem sido implicada no aumento sérico de algumas enzimas. Alguns autores encontraram prevalência de 13% e os outros, 22% e até 53% de alterações para as fosfatases alcalinas. Objetivo; As metas deste trabalho são determinar a proporção de alterações amostrais nas atividades das gama-glutamil transferase (GGT), fosfatases alcalinas totais (FA), transaminases (AST e ALT) e as concentrações séricas da carbamazepina em pacientes de ambulatórios de epilepsia. Metodologia: 0 desenho do estudo é descritivo, aprovado pelo Comitê de Ética local, no qual uma amostra de conveniência de 52 pacientes epilépticos de acompanhamento ambulatorial foi organizada por faixa etária de 12 a 30 e de 31 a 90 anos e, subdivididos por tempo de uso. As atividades séricas das GGT, FA, AST e ALT foram determinadas, assim como, as concentrações séricas da carbamazepina. As proporções de alterações por variáveis foram descritas. Resultados: 52% dos pacientes apresentaram alteração em pelo menos uma enzima, 42% com alterações nas FA, 18%, nas GGT, 12% nas AST e 2%, nas ALT. A faixa etária de 12 a 30 anos apresentou 56% de alterações nas FA enquanto que aquela de 31 a 90 anos, apenas 18%. Conclusão: a faixa etária pode colaborar com o aumento de prevalência das fosfatases alcalinas alteradas nestes pacientes. Quanto aos baixos valores para GGT e transamin / Carbamazepine is the drug utilized in the treatment of patients who bear epilepsy with secondary generalization. Furthermore, carbamazepine has been implicated with the serum increase of certain enzymes. Some authors have found a prevalence of 13% while others have found 22%, or even 53% of alterations for alkaline phosphatases. Objective: the goals of this study are to determine the ratio of alterations of the serum activities of the enzymes gamma-glutamil transferase (GGT), alkaline phosphatases (AF) and transaminases (AST, aspartate aminotransferase; and ALT, alanine aminotransferase) were determined as well as the serum concentrations of carbamazepine in samples taken from the metropolitan region of Salvador, Bahia. Methodology: the design of this study is descriptive and it has been approved by the local Ethics Committee. A convenience sample of 52 epileptic ward patients was distributed according to age groups of 12 to 30 and 31 to 90 years-old, and was also subdivided according to the period of usage. The serum activities of the enzymes GGT, AF, AST, and ALT were determined as well as the serum concentrations of carbamazepine. The proportions of alterations per variables were described. Results: 52% of the patients showed alteration in at least one enzyme, 42% with alterations in the AF, 18% in the GGT, 2% in the ALT, and 12% in the AST. The age group of 12 to 30 years-old showed 56% of the alterations in AF while the group of 31 to 90 year olds showed only 18% alterations. Conclusion: age group may contribute to the increase of prevalence of altered alkaline phosphatases in these patients. In regard to the low values 70 altered alkaline phosphatases In these patients. In regard to the low values of GGT and transaminases, futher studies would be necessary for better understanding of those variations.